| cfDNA | Cell-free DNA |
| CNI | Copy number instability |
| CSC | Cancer stem cells |
| CT scan | Computed-tomography scanner |
| CTLA-4 | Cytotoxic T-lymphocyte-associated antigen 4 |
| ECOG | Eastern cooperative oncology group |
| Fc | Crystallizable fragment |
| FcR | Crystallizable fragment receptor |
| HNSCC | Head and neck squamous cell carcinoma |
| ICI | Immune checkpoint inhibitor |
| iRECIST | Immune response-evaluation criteria in solid tumors |
| irRC | Immune-related response criteria |
| irRECIST | Immune-related response-evaluation criteria in solid tumors |
| NGS | Next-generation sequencing |
| NSCLC | Non-small-cell lung cancer |
| OS | Overall survival |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed cell death ligand 1 |
| PD-L2 | Programmed cell death ligand 2 |
| RECIST | Response-evaluation criteria in solid tumors |
| TAM | Tumor-associated macrophage |
| TGK | Tumor growth kinetics |
| TGR | Tumor growth rate |
| TILs | Tumor-infiltrating T lymphocytes |
| Tregs | Regulatory T-cells |
| TTF | Time to treatment failure |
| uPD | Unconfirmed progressive disease |